SGLT2 Inhibition and Heart Failure: Translating the Evidence to Clinical Practice

Educational Activity

This program addresses the following needs of clinicians who treat patients with heart failure (HF):

  1. To interpret the increasing number of analyses of subsets of data from SGLT2 inhibitor clinical trials in patients with HF with reduced ejection fraction (HFrEF) which are providing insights into their optimal utilization in HFrEF patients
  2. To indicate the renal benefits of SGLT2 inhibitors in patients with HFrEF as well as in other patients with related diseases such as those with chronic kidney disease (CKD) (up to 50% of HFrEF patients have CKD) and atherosclerotic cardiovascular disease (ASCVD)
  3. To establish and expand a knowledge base of practical considerations for using SGLT2 inhibitors in HFrEF patients, and
  4. To assess the emerging evidence with, and recognize ongoing clinical investigations of, SGLT2 inhibitors in patients with HF with preserved ejection fraction (HFpEF). Information on best uses of SGLT2 inhibitors for patients with HF will be disseminated through lecture, interactive case presentation, panel discussion, and question-and-answer with experts.

 

This educational activity is intended for Physicians, Nurses, Nurse Practitioners, Pharmacists, Scientists, and Health Care Professionals who specialize or have an interest in heart failure.

 

This activity is supported through an educational grant from AstraZeneca Pharmaceuticals.

 

Original recording Date: September 12, 2021

 

 

 

 

 

 

 

 

 

Upon completion of the activity, participants will demonstrate improved competence and ability to:

 

  • Interpret analyses of cardiovascular endpoints from subsets of data from HFrEF outcome trials with SGLT2 inhibitors
  • Recognize the renoprotection of SGLT2 inhibition in a broad spectrum of patients with HFrEF, CKD, and cardiovascular disease
  • Identify practical considerations for use of SGLT2 inhibitors in patients with HFrEF
  • Explain the rationale, trial designs, and emerging evidence for SGLT2 inhibition in patients with HFpEF

Accreditation Statement

 

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

The Heart Failure Society of America designates this enduring educational activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Learners should claim only the credit commensurate with the extent of their participation in the activity.
 

LO_Icon

Credits Available

CME, CNE, & CPE

Powered by Oasis.